Xianmei Zhong

Ms. Xianmei Zhong

orcid

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
11 September 2022 in Molecules
Verified
Journal Article
Open access
PDF file
JLJing Li
Jing Li
XZXianmei Zhong
Xianmei Zhong
YZYUESHUI ZHAO
YUESHUI ZHAO
JSJing Shen
Jing Shen
CPChalermchai Pilapong
Chalermchai Pilapong
ZXZhangang Xiao
Zhangang Xiao
Lung cancer is the second leading cause of cancer-related death worldwide. In recent decades, investigators have found that microRNAs, a group of non-coding RNAs, are abnormally expressed in lung cancer, and play important roles in the initiation and progression of lung cancer. These microRNAs have been used as biomarkers and potential therapeutic targets of lung cancer. Polyphenols are natural and bioactive chemicals that are synthesized by plants, and have promising anticancer effects against several kinds of cancer, including lung cancer. Recent studies identified that polyphenols exert their anticancer effects by regulating the expression levels of microRNAs in lung cancer. Targeting microRNAs using polyphenols may provide a novel strategy for the prevention and treatment of lung cancer. In this review, we reviewed the effects of polyphenols on oncogenic and tumor-suppressive microRNAs in lung cancer. We also reviewed and discussed the potential clinical application of polyphenol-regulated microRNAs in lung cancer treatment.

11 November 2022 in Pharmaceuticals
Verified
Journal Article
Open access
PDF file
FCFangshan Chen
Fangshan Chen
XZXianmei Zhong
Xianmei Zhong
QDQian Dai
Qian Dai
KLKuo Li
Kuo Li
WZWei Zhang
Wei Zhang
JLJing Li
Jing Li
The TNF-related apoptosis-inducing ligand (TRAIL) could induce apoptosis of leukemic cells, while showed no cytotoxic effect on normal cells. One of the limitations for application of recombinant TRAIL (rhTRAIL) in leukemia treatment is that the serum half-life of this protein is short. Gene delivery is a good strategy to prolong the half-life of TRAIL. In this study, we genetically engineered umbilical cord-MSCs to continuously express and secrete soluble TRAIL (MSC-sTRAIL), to investigate the effects of MSC-sTRAIL on B-cell acute lymphocytic leukemia (B-ALL) cells. In vitro, MSC-sTRAIL significantly inhibited the proliferation of B-ALL cells by suppressing PI3K/AKT and MEK/ERK signaling pathways, and induced apoptosis of B-ALL cells via the caspase cascade-mediated pathway and mitochondrial-mediated pathway. In vivo, MSC-sTRAIL dramatically inhibited B-ALL cell growth. Meanwhile, B-ALL-induced splenic and renal injuries were significantly alleviated after MSC-sTRAIL treatment. Moreover, the serum levels of MSC-secreted sTRAIL were still high in MSC-sTRAIL treated mice, indicating an extended half-life of sTRAIL. Our study suggests that MSC delivered-TRAIL secretion is a potential therapeutic strategy for B-ALL treatment.

1 July 2025 in Scientific Reports
Verified
Journal Article
Open access
PDF file
FRFenglian Ren
Fenglian Ren
YWYihua Wang
Yihua Wang
CHChangyang He
Changyang He
XZXi Zheng
Xi Zheng
CZchunyang zhou
chunyang zhou
XZXianmei Zhong
Xianmei Zhong
This study aims to elucidate the potential mechanisms underlying the therapeutic effects of Bletilla striata in glioma. Targets of Bletilla striata and glioma were predicted using TCMSP, SwissTargetPrediction, GeneCards, and other databases. A “drug-ingredient-target” network and protein–protein interaction (PPI) network were constructed, with core targets identified via topological analysis. Functional enrichment (GO/KEGG, DAVID), molecular docking, and experimental validations (MTT, scratch assay, RT-PCR, Western blot) were performed. A total of 11 active ingredients of Bletilla striata, 456 corresponding targets, and 2,830 glioma-related targets were identified. Nine core targets (AKT1, STAT3, mTOR, etc.) were identified. GO analysis indicated that these targets were primarily involved in phosphorylation, protein binding, and the positive regulation of RNA polymerase II transcription. KEGG analysis highlighted key pathways, including pathways in cancer, the PI3K-AKT signaling pathway, and microRNA-related regulatory mechanisms in cancer. Molecular docking analysis demonstrated high binding affinities between active ingredients and core targets, particularly AKT1 and mTOR. Functional assays showed that Blestriarene A, a key active compound in Bletilla striata, significantly suppressed glioma cell proliferation and migration. RT-PCR results indicated that treatment with varying concentrations of Blestriarene A for 48 h downregulated AKT mRNA expression while upregulating mTOR mRNA expression. Western blot analysis further confirmed a reduction in PI3K, AKT, and mTOR phosphorylation following treatment. Network pharmacology and in vitro experiments suggest that Blestriarene A anti-glioma effects by modulating the PI3K/AKT/mTOR signaling pathway.

11 September 2026 in Frontiers in Public Health
Verified
Journal Article
Open access
PDF file
HLHongjiao Li
Hongjiao Li
XFXin Feng
Xin Feng
XZXi Zheng
Xi Zheng
XZXianmei Zhong
Xianmei Zhong
Objective: This study systematically evaluates the construction methods, predictive factors, and performance of risk prediction models for anti-tuberculosis drug-induced liver injury (ATB-DILI). It aims to furnish evidence-based evidence for early detection of East Asian individuals at high risk of ATB-DILI and the development of personalized clinical treatment plans. Methods: A comprehensive literature search was conducted to identify studies related to risk prediction models for ATB-DILI. Key data, including study population, sample size, model construction algorithms, predictive factors, and model discrimination, were extracted. Qualitative synthesis and systematic analysis were then performed. Results: A total of 26 studies comprising 31 risk prediction models (cumulative sample size approximately 41,734 cases) were included. Twenty studies reported internal validation and six reported external validation. Model discriminative ability varied from 0.624 to 1.0, indicating at least modest-to-excellent discriminatory ability. Prediction model Risk Of Bias ASsessment Tool (PROBAST) assessment identified only one study at low risk of bias, with all remaining studies rated high risk of bias. Meta-analysis yielded a pooled AUC of 0.81 for ATB-DILI prediction models. History of liver disease, extrapulmonary tuberculosis, age ≥60 years, alcohol consumption, concomitant medication use, retreatment, elevated AST, diabetes, and smoking were associated with higher ATB-DILI risk (all P < 0.05), whereas uric acid showed an inverse association ( P < 0.05). Importantly, the observed association for non-use of hepatoprotective agents cannot confirm a preventive effect; these factors should inform risk stratification and intensified monitoring rather than guide prophylactic hepatoprotective therapy. Conclusion: Published risk prediction models for ATB-DILI among East Asian populations were systematically appraised. These models yielded moderate-to-good discriminative performance yet showed substantial heterogeneity and high risk of bias, mainly due to defective missing-data processing, univariate-based predictor selection, insufficient outcome events, and absent external validation. Such methodological shortcomings may overestimate AUC values, especially for retrospective non-validated models. Existing ATB-DILI prediction models are thus of uncertain reliability and generalizability. Future large-sample multicenter prospective studies with standardized outcomes and external validation are required to develop robust clinically applicable models. Systematic review registration: https://www.crd.york.ac.uk/PROSPERO/view/CRD420261468400 , identifier CRD420261468400.